GW’s Epidiolex results are worth mentioning

Whenever one of my biotech companies have good news. It almost always makes me smile. Yesterday it was GW.┬áThe shares of GW Pharmaceuticals (GWPH) are soaring on news that its cannabis-derived drug significantly diminished the seizure amount in children with a rare form of epilepsy in a phase-three trial. Epidiolex…

Continue reading